CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Member Units Previously Reported	Member Units Reverse capitalization	Member Units Effect of reverse capitalization	Member Units	Preferred Stock Series C Previously Reported	Preferred Stock Series C Reverse capitalization	Common Stock Class A Common Stock	Common Stock Class V Common Stock	Additional Paid-in Capital Reverse capitalization	Additional Paid-in Capital Effect of reverse capitalization	Additional Paid-in Capital	Accumulated Deficit Previously Reported	Accumulated Deficit Effect of reverse capitalization	Accumulated Deficit	Noncontrolling Interests Previously Reported	Noncontrolling Interests	Previously Reported	Effect of reverse capitalization	Total
Balance at beginning of period at Dec. 31, 2020					$ 21,477	$ (21,477)			$ 21,477	$ 21,477		$ (184,682)	$ (184,682)				$ (163,205)	$ (163,205)
Balance at beginning of period (in shares) at Dec. 31, 2020	1,166	104,377	105,543		491	(491)
Increase (decrease) in members equity
Consolidated net loss														$ (3,910)					$ (3,910)
Equity based compensation											$ 509								509
Distributions														(81)					(81)
Balance at end of period at Mar. 31, 2021											21,986			(188,673)					(166,687)
Balance at end of period (in shares) at Mar. 31, 2021				105,543
Balance at beginning of period at Dec. 31, 2021					$ 21,477	$ (21,477)			$ 21,477	$ 21,477		(211,168)	$ (211,168)				(189,691)	$ (189,691)
Balance at beginning of period (in shares) at Dec. 31, 2021	1,149	103,709	104,858		491	(491)
Increase (decrease) in members equity
Consolidated net loss												(12,036)		(12,302)	$ (11,779)	$ (11,901)	(23,815)		(24,203)
Equity based compensation											402								402
Issuance of common stock upon exercise of stock option awards, net of shares withheld for income taxes											29								29
Issuance of common stock upon exercise of stock option awards, net of shares withheld for income taxes (in shares)							25
Issuance of common stock and common stock warrants upon the reverse recapitalization, net of issuance costs							$ 4	$ 7			206,253					(64,656)			141,608
Issuance of common stock and common stock warrants upon the reverse recapitalization, net of issuance costs (in shares)				(104,858)			46,832	69,781
Issuance of common stock upon exercise of warrants							$ 1				9,330								9,331
Issuance of common stock upon exercise of warrants (in shares)							5,079
Distributions														(183)					(183)
Balance at end of period at Mar. 31, 2022							$ 5	$ 7			$ 237,433	$ (223,387)		$ (223,653)	$ (76,435)	$ (76,557)	$ (62,377)		$ (62,765)
Balance at end of period (in shares) at Mar. 31, 2022							51,936	69,781